KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Cash from Financing Activities (2016 - 2025)

Novavax (NVAX) has 16 years of Cash from Financing Activities data on record, last reported at -$6.6 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 92.99% year-over-year to -$6.6 million; the TTM value through Dec 2025 reached $27.7 million, down 89.36%, while the annual FY2025 figure was $27.7 million, 89.36% down from the prior year.
  • Cash from Financing Activities reached -$6.6 million in Q4 2025 per NVAX's latest filing, down from $42.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $577.0 million in Q1 2021 and bottomed at -$354.4 million in Q1 2023.
  • Average Cash from Financing Activities over 5 years is $54.0 million, with a median of $2.3 million recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: tumbled 321.67% in 2023, then surged 43854.64% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at -$60.7 million in 2021, then soared by 415.33% to $191.4 million in 2022, then plummeted by 47.56% to $100.4 million in 2023, then crashed by 103.41% to -$3.4 million in 2024, then crashed by 92.99% to -$6.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$6.6 million in Q4 2025, $42.4 million in Q3 2025, and -$1.0 million in Q2 2025.